Skip to main content
GH logo

GH · Guardant Health, Inc.

Track GH — free
$145.59 +0.45 (+0.31%) At close · Nov 19
Market Cap
$19.70B
Shares
135.29M
Volume · Nov 19 1.87M Avg daily vol (3M) 1.98M

Price & Indicators

 

Key stats

Close
$145.59
Open
$148.50
Day range
$145.40–155.97
52-week closing range
$78.60–187.22
Average volume, 30 days
2.1M
Short interest
9.4M · 7.0% of shares · 5.4 days
Short volume, last session
54%
Last earnings
Nov 5, 2026
Latest filing
10-Q · Nov 5
Price history
Jan 2020 to Nov 2026

Up next

Feb 18, 2027 Est · unconfirmed · in 13 wks

Latest documents

2026
Nov 16
Current report 8-K Events of Nov 11
Completes $550 Million 0% Convertible Notes Offering Due 2032

Guardant Health completed a $550 million private offering of 0% convertible senior notes due 2032. Net proceeds of approximately $538.3 million were used in part to repurchase $395.2 million of its 2027 convertible notes.

Entered into a material agreement, New debt or off-balance-sheet obligation, Unregistered sale of equity, Other events Read from the first part of this long document
3 source passages
On November 16, 2026, Guardant Health, Inc. (the “Company”) completed its previously announced private offering (the “Offering”) of $550 million aggregate principal amount of 0% Convertible Senior Notes due 2032 The net proceeds from the Offering, after deducting the initial purchasers’ discounts and commissions and the Company’s estimated offering expenses, were approximately $538.3 million. The Company used approximately $501.7 million of the net proceeds from the Offering to repurchase for cash approximately $395.2 million aggregate principal amount of its existing 0% Convertible Senior Notes due 2027 Open the document at this passage
Nov 5
Earnings call
Raises 2026 revenue guidance to $1.36 to $1.37 billion

Guardant Health raised full-year 2026 revenue guidance to $1.36 to $1.37 billion, after reporting third-quarter revenue of $361.0 million; screening revenue reached $68 million and oncology revenue reached $231 million.

4 source passages
Total revenue: the transcript reads “$351 million”, but the company's 8-K filed 2026-11-05 reports $361.0 million. we're raising our full-year 2026 revenue guidance to a range of $1.36 to $1.37 billion. Screening revenue was $68 million Oncology revenue was $231 million Open the document at this passage
Nov 5
Quarterly report 10-Q FY2026 Q3, ended Sep 30
Revenue rose 36% as Shield screening revenue surged 180%

Guardant Health reported revenue of $361.0 million for the three months ended September 30, 2026, up 36% from $265.2 million for the three months ended September 30, 2025. Shield screening revenue rose 180% to $67.6 million.

Revenue $360.98M ▲ 36.1% Net loss $124.36M Diluted EPS -$0.93
Read from the MD&A section
3 source passages
Total revenue was $361.0 million for the three months ended September 30, 2026, compared to $265.2 million for the three months ended September 30, 2025, an increase of $95.8 million, or 36%. Screening revenue was $67.6 million for the three months ended September 30, 2026, compared to $24.1 million for the three months ended September 30, 2025, an increase of $43.5 million, or 180%. The increase was driven primarily by an increase in our Shield screening test volume to approximately 83,000 for the three months ended September 30, 2026 from approximately 24,000 for the three months ended September 30, 2025. Open the document at this passage
Nov 5
Current report 8-K
Revenue grew 36%; 2026 guidance raised

Guardant Health reported third-quarter revenue of $361.0 million, up 36%, and raised 2026 revenue guidance to $1.36 to $1.37 billion, representing 38% to 40% growth.

Financial results
2 source passages
Reported total revenue of $361.0 million, an increase of 36%, driven by: Guardant Health now expects full year 2026 revenue to be in the range of $1.36 to $1.37 billion, representing growth of 38% to 40% compared to full year 2025. Open the document at this passage
Nov 3
Current report 8-K Events of Nov 2
Kevin R. Sayer appointed as board expands to 11

Guardant Health expanded its board to 11 by appointing Kevin R. Sayer effective November 2, 2026, and appointed Robert A. Parks Chief Accounting Officer. Sayer will receive a $500,000 restricted stock unit award and a $60,000 per year cash retainer.

Director or officer change, or executive pay
4 source passages
On November 2, 2026, the Board of Directors (the “Board”) of Guardant Health, Inc. (the “Company”) increased the number of directors on the Board to 11 and appointed Kevin R. Sayer, 68, as a Class II director of the Company, to be effective as of November 2, 2026. On November 2, 2026, the Board appointed Robert A. Parks as Chief Accounting Officer and he assumed the role of principal accounting officer of the Company. Mr. Sayer will receive the standard compensation paid by the Company to all of its non-employee directors under the Company’s Eligible Director Compensation Program (the “Program”). Pursuant to the Program, Mr. Sayer will receive a restricted stock unit award with a value of $500,000 (the “Initial Award”). In addition, Mr. Sayer will receive a cash retainer of $60,000 per year for service as a director. Open the document at this passage
All documents

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$1.28B
Trailing 12 months
Net income (TTM)
−$485.07M
Trailing 12 months
Revenue growth YoY
+36.1%
Year over year
Operating margin
-39.4%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
-1.2%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
−$475.56M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+7.7%
Year over year · more shares
Price change (1Y)
+46.2%
Trailing year
Short interest
7.0%
Latest settlement · 5.4 days to cover
View all 125 metrics

AI Brief

Q3 FY26 earnings call · Nov 5, 2026
Q3 FY26

TL;DR. Third-quarter revenue grew 36%, full-year revenue and screening guidance were raised, oncology-volume guidance increased to more than 50%, non-GAAP gross-margin guidance increased to 65%, SHIELD costs and coverage improved, and Guardant360 CDx received an additional major approval. GAAP net loss and operating expenses increased, full-year operating-expense and free-cash-flow burn guidance worsened, and management expects Shield ASP to tick down.

Bullish
  • + SHIELD cost per test fell from $410 in Q2 to $330 in Q3, surpassing the $350 year-end target a quarter early. new
  • + Expanded SHIELD coverage is expected to provide access for approximately 100 million people, representing more than 80% of the eligible U.S. screening population in 2027. new
  • + Guardant360 CDx received FDA approval for ETCAMAH and CE marking in Europe. new
  • + Full-year non-GAAP gross-margin guidance increased to 65%. new
Bearish
  • − GAAP net loss increased to $124.4 million from $92.7 million. new
  • − Full-year free-cash-flow burn guidance increased to $205 million-$220 million from $195 million-$205 million.

AI-generated from the earnings call and 8-K · may contain errors · not investment advice

Equibles Rating

blended score · not investment advice
Overall
Neutral
SellHoldBuy
Technical Sell Momentum Strong Sentiment Bullish Fundamentals Weak Quant / Vol Very High
Market backdrop VIX 28.4 · fear Equity put/call 0.72
Technical
price trend
Sell
50 / 200-day cross No cross
Price vs 200-day avg +9%
above
Price vs 50-day avg −13%
below
RSI (14) 36
neutral
MACD trend Negative
52-week position 62%
mid-range
Momentum
relative strength
Strong
1-month return −11%
trailing
6-month return +13%
trailing
YTD return +43%
this year
Relative strength +18%
vs S&P · 6-mo
Sentiment
smart money
Bullish
Trend (MA cross) No cross
50d $167 › 200d $133 — 50d above 200d
Institutional flow Accumulating
+11% holders QoQ · +139 funds added
Insider flow Distributing
Net -$3.2M over 90 days · 100% sells
Short interest Falling
6.97% of shares out · ▼ -19.2% MoM · 5.4 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
680 holders — near 3-yr high, broad support
Squeeze score 63
elevated · 0–100
Fundamentals
Weak
Revenue growth +33%
Y/Y
EPS growth +7%
Y/Y
Free cash flow $-233.1M
Balance sheet $1.1B
net debt
Quant / Vol
risk profile
Very High
Volatility 53%
annualized · 1-yr
Max drawdown −33%
past year
ATR 6.5%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

Beat or met 4 of last 4
Latest guidance · from the Earnings Call filed Nov 5, 2026
full-year 2026
Revenue Raised $1.36B – $1.37B
Jul 30, 2026 $1.34B – $1.36B changed to Nov 5, 2026 $1.36B – $1.37B
prior FY $982.02M midpoint +39.0% Y/Y
Oncology revenue growth Maintained 30%
Jul 30, 2026 30% changed to Nov 5, 2026 30%
Oncology volume growth at least 50%
Non-GAAP gross margin Non-GAAP Raised 65%
Jul 30, 2026 64% – 65% changed to Nov 5, 2026 65%
Screening revenue Raised $233M – $238M
Jul 30, 2026 $218M – $230M changed to Nov 5, 2026 $233M – $238M
2026
Non-GAAP operating expenses Non-GAAP Raised $1.11B – $1.13B
May 7, 2026 $1.05B – $1.07B changed to Nov 5, 2026 $1.11B – $1.13B
Previous outlook earlier release · from the Earnings Call filed Jul 30, 2026

Still-open targets the latest release did not restate under the same label.

Oncology volume growth · full-year 2026 50%
Full year non-gap gross margin · full-year 2026 64% – 65%
2026 non-gap operating expenses · 2026 $1.08B – $1.1B
Guided vs delivered · last 4 settled
Full year 2025 revenue full year 2025
guided $965M – $970M
$982.02M Beat +1.5%
Full year 2023 revenue full year 2023
guided $553M – $556M
$563.95M Beat +1.7%
Full year 2022 revenue full year 2022
guided $440M – $450M
$449.54M In line
Revenue full year 2021
guided $360M – $370M
$373.65M Beat +2.4%

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Sell
2 · 3 · 1
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
+9% Bullish
Price vs 50-day avg
−13% Bearish
RSI (14)
36 Neutral
MACD trend
Negative Bearish
52-week position
62% Neutral
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross) No cross
50d $167 › 200d $133 — 50d above 200d
Institutional flow Accumulating
+11% holders QoQ · +139 funds added
Insider flow Distributing
Net -$3.2M over 90 days · 100% sells
Short interest Falling
6.97% of shares out · ▼ -19.2% MoM · 5.4 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
680 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $79 Now $146 · 62% Range high $187
vs 200-day avg +9% vs 50-day avg -13%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings
Metric Latest Period YoY
Adjusted EBITDA non-GAAP -152.07M Nine Months Ended September 30, 2026 —
Non-GAAP loss from operations non-GAAP -180.32M Nine Months Ended September 30, 2026 —
Non-GAAP net loss non-GAAP -153.66M Nine Months Ended September 30, 2026 —
Non-GAAP net loss per share, basic and diluted non-GAAP -$1.16 Nine Months Ended September 30, 2026 —
Shield tests 83,000 the third quarter of 2026 —
Shield screening test volume 66,000 the three months ended June 30, 2026 filing —
Shield screening tests 66,000 Q2 2026 —

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Diagnostics & Research — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
GH
Guardant Health, Inc.
this stock
$19.70B +42.5% +32.9% — 7.0%
TMO
Thermo Fisher Scientific Inc.
$255.19B +18.9% +14.5% 36.3 1.3%
DHR
Danaher Corp
$160.10B -0.6% +8.5% 37.2 1.2%
IDXX
Idexx Laboratories Inc
$54.33B +1.9% +10.4% 46.5 3.0%
A
Agilent Technologies, Inc.
$49.43B +28.9% +6.4% 34.5 1.7%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Reducing
Holders
680
% held
98.2%
Net QoQ
-1.1M sh
Top holder
BlackRock, Inc.
Held Float
View
Held by Funds
Fund positions
641
View
Short & Settlement
Short Interest Falling
Shares short
9.4M
Days to cover
5.4d
Change
-2.2M sh
View
Short Volume
Short vol %
54%
As of
Nov 19, 2026
Short Total
View
Fails to Deliver
FTD shares
318
Value
$56.6K
As of
Oct 28, 2026
View
Off-Exchange
Off-exchange %
49.9%
Week of
Oct 12, 2026
Off-exch Lit
View
Smart Money
Insider Trades Net selling
Net (90d)
-$3.2M
Buyers / Sellers
0 / 3
Buyers Sellers
View
Congressional Trades Buy
Member
Jonathan Jackson
Amount
$15.0K–$50.0K
Traded
Sep 28, 2026
View
Financials
Financials
Revenue (FY)
$982.0M
Net income (FY)
$-416.3M
EPS diluted
$-3.32
View
Filings
SEC Filings
Latest
8-K
Filed
Nov 16, 2026
This year
25

Guardant Health completed a $550 million private offering of 0% convertible senior notes due 2032. Net proceeds of approximately $538.3 million were used in part to repurchase $395.2 million of its 2027 convertible notes.

View
Proposed Sales
Value
$547.1K
Shares
3.8K
Filed
Nov 18, 2026
View
Earnings & Events
Webcasts
Last webcast
Nov 18, 2026
View
Investor Relations
Latest news
Guardant Health Launches Guardant…
Published
Nov 19, 2026
Upcoming events
1
View

Performance

5D 20D 120D MTD YTD
GH -6.0% -10.7% +12.7% -18.6% +42.5%
SPY -5.5% -6.3% -5.6% -5.3% +5.0%
vs SPY -0.5% -4.4% +18.4% -13.3% +37.6%
Key facts CIK 1576280 CUSIP 40131M109 13F (30d) 657 filings 604 filers Visit website Investor relations